Cargando…
Osimertinib: A Review in Previously Untreated, EGFR Mutation-Positive, Advanced NSCLC
Activating mutations in the epidermal growth factor receptor (EGFR) gene have been identified as key oncogenic drivers of non-small cell lung cancer (NSCLC). Osimertinib (Tagrisso(®)) is an orally administered, third-generation EGFR tyrosine kinase inhibitor (EGFR-TKI) that is widely approved for th...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8536603/ https://www.ncbi.nlm.nih.gov/pubmed/34564820 http://dx.doi.org/10.1007/s11523-021-00839-w |